Efficacy and safety of lactosaminated human serum albumin-adenine arabinoside monophosphate in chronic hepatitis B patients non-responders to interferon therapy: a randomised clinical trial.
Zarski
J P
JP
Barange
K
K
Souvignet
C
C
Bertini
M
M
Marcellin
P
P
Tran
A
A
Deugnier
Y
Y
Couzigou
P
P
Plages
A
A
Ambroise-Thomas
P
P
D000328:Adult; D004338:Drug Combinations; D004351:Drug Resistance; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019233:Retreatment; D012709:Serum Albumin / Q000627:therapeutic use*; D001084:Vidarabine Phosphate / Q000627:therapeutic use*
D004338:Drug Combinations; D012709:Serum Albumin; C046912:lactosaminated serum albumin; D001084:Vidarabine Phosphate; D007372:Interferons